ABOUT CORDIS
Resilient growth in a
defensive sector
The Cordis Global Medical Technology Fund was launched by a team of professional investors, leading clinical physicians, and medical device industry specialists to capitalise on the specialised sub-sector of listed global companies which make medical devices that provide treatments for critical chronic disease.
The Fund provides an investment opportunity for clients targeting resilient long-term growth in a defensive sector of the market.
GENESIS OF CORDIS
An investment fund established to harness the secular shift in healthcare treatment paradigms.
Or what we like to call the Revolution in Medical Technology.
It was the studied observation of Professor Michael Vallely and Michael Cartmill over many years that the use of sophisticated medical technology for treatment of critical chronic disease has been steadily climbing. The inflection point in MedTech adoption was reached later than the rest of the technology sector due to years of clinical trials and thousands of hours of required operating theatre time. It was during this period that conviction was built up in the safety and efficacy profile of devices. Importantly, this period also allowed the time to build the case that these devices offered overall cost savings to the healthcare system due to significantly reduced surgery times and lower readmission rates. This Revolution in Medical technology has become the answer to world’s problem with burgeoning healthcare budgets.
The Founders recognised this as one of the most intuitively logical and resilient growth opportunities, underwritten by a universal desire of the world’s ageing population to live a longer and better-quality of life. Pairing the undeniable tailwinds of healthcare demand with the safest, most effective and lowest cost solution, bred the genesis of Cordis Asset Management.